Parkinson’s Disease: Epidemiological pattern of hospital admission
DOI:
https://doi.org/10.33448/rsd-v11i1.24535Keywords:
Parkinson's Disease; Epidemiology; Hospital admission.Abstract
Introduction: Parkinson's Disease (PD) is among the fastest growing neurological disorders in the world, characterized as the second most prevalent neurodegenerative disease. In Brazil, notification of PD is not mandatory, which makes it difficult to estimate its prevalence in the country. Objective: To outline the epidemiological profile of hospitalizations related to PD in Brazil, associating age group, sex of individuals affected with PD, time, character (urgent and elective) and hospitalization costs. Methodology: This was a descriptive, retrospective epidemiological study with a quantitative approach, with data obtained through consultation with the Department of Informatics of the Unified Health System (DATASUS). The population of interest was individuals with PD, reported in Brazil between January 2016 and December 2020, with a focus between 60 and 89 years old. Results and Discussion: It was found between 2016 and 2020, the highest number of admissions of individuals with PD occurred with patients aged 60 to 79 years, with males being more affected by the number of admissions and deaths. The Southeast showed the highest number of hospitalizations and the Northeast the highest average length of stay. The total number of deaths was 281, generating costs of 19 million reais. Conclusion: The data obtained revealed patterns that remain stable over the years, according to region, gender, deaths and age group, although there are possible problems with underreporting and lack of information. Thus, the need for further studies for future delineations of the epidemiological patterns of PD in Brazil is clear.
References
Alho, A. T. (2011). Caracterização da substância negra humana durante o envelhecimento. Faculdade de Medicina da Universidade de São Paulo.
Albuquerque, C. (2020). Pandemia diminui número e muda perfil de internações no SUS em 2020. Observatório de Política e Gestão Hospitalar. https://www.observatoriohospitalar.fiocruz.br/debates-e-opinioes/pandemia-diminui-numero-e-muda-perfil-de-internacoes-no-sus-em-2020.
Benito-León, J. (2018). Epidemiología de la enfermedad de Parkinson em España y su contextualizacíon mundial. Revista de Neurología. 66 (4).
Borges, V. & Tosta, E. (2010). Recomendações para o tratamento da fase inicial da doença de Parkinson. Doença de Parkinson: recomendações. 3, 19-37.
Bovolenta, T. M. & Felício, A. C. (2016). Parkinson’s patients in the Brazilian Public Health Policy Context. Editorial – Hospital Israelita Albert Einstein.
Brasil, M. S. (2021). Ministério da Saúde DATASUS. Banco de dados do Sistema Único de Saúde-DATASUS. https://datasus.saude.gov.br/informacoes-de-saude-tabnet/.
Brasil, M. S. (2021). Ministério da Saúde DATASUS Faixa Etária. Banco de dados do Sistema Único de Saúde-DATASUS. http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/niuf.def.
Brasil, M. S. (2021). Ministério da Saúde DATASUS Valor Total. Banco de dados do Sistema Único de Saúde-DATASUS. http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/niuf.def.
Brasil, M. S. (2021). Ministério da Saúde DATASUS Caráter de Atendimento. Banco de dados do Sistema Único de Saúde-DATASUS. http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/niuf.def.
Chagas, N. H. M., Zuardi, W. A., Tumas, V., Pena-Pereira, M. A., Sobreira, T. E., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E. C. & Crippa, J. A. S. (2014) Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial. Journal of Psychopharmacology. 28(11), 1088-192.
Crippa, S. A. J., Hallak J. E. C., Zuardi, A. W., Guimarães, F. S., Tumas, V. & dos Santos, R. G. (2019). Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?. European Archives of Psychiatry and Clinical Neuroscience. 269, 121-133.
Crippa, J. A., Guimarães, F. S., Campos, A. C. & Zuardi, A. W. (2018). Translational investigation of the therapeutic potential of cannabidiol (CBD): Towards a new age. Frontiers in Imumunology. 9.
Dong, J., Cui, Y., Li, S. & Le, W.. (2016) Current Pharmaceutical Treatments and Alternative Therapies of Parkinson’s Disease. Current Neuropharmacology. 14(4).
Dorsey, E. R., Sherer, T., Okun, M. S. & Bloem, B. R.. (2018). The Emerging Evidence of the Parkinson Pandemic. Journal of Parkinson’s Disease. 8, 3-8.
Dorsey, E. R. & Elbaz, A. (2018) Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 17. 939-53.
Embrapa Territorial (2020). Sistema de Inteligência Territorial Estratégica da Macrologística Agropecuária brasileira (SITE-MLog). Campinas. www.embrapa.br/macrologistica.
Fahn, S. & Kang, J. (2018). Doença de Parkinson. In: Louis D. Merrit – Tratado de Neurologia. 13ª Edição. 83, 702-720.
Fernandes, I. & Filho, A. S. (2018). Estudo Clínico-Epidemiológico de Pacientes com Doença de Parkinson em Salvador-Bahia. Revista Brasileira de Neurologia e Psiquiatra, 22(1).
Ferreira-Junior, N. C., Campos, A. C., Guimarães, F. S, Del-Bel, E., Zimmermann, P. M. R., Junior, L. B., Hallak, J. E., Crippa, J. A. & Zuardi, A. W. (2020). Biological bases for a possible effect of cannabidion in Parkinson’s disease. Brazilian Journal of Psychiatry, 42(2), 218-224.
Gil, A. C. (2002). Como elaborar projetos de pesquisa. 4. ed. São Paulo: Atlas.
IBGE – INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATÍSTICA (2020). Censo Brasileiro de 2010.
Lubomski, M. Rushworth, R. L. & Tisch, S. (2015). Hospitalisation and comorbidities in Parkinson’s disease: a large Australian retrospective study. Journal of Neurology, Neurosurgery & Psychiatry, 86, 324-330.
Leiva, A. M., Martinez-Sanguinetti, M. A. M., Troncoso-Pantoja, C. Nazar, G., Petermann-Rocha, F. & Celis-Morales, C. (2019). Chile lidera el ranking latino americano de prevalencia de enfermedad de Parkinson. Revista de Medicina Chile. 147(4).
Peres, F. F., Lima, A. C., Hallak, J. E. C., Crippa, J. A., Silva, R. H. & Abílio, V. C. (2018). Cannabidiol as a Promising Strategy to treat and Prevent Movement Disorders?. Frontiers in Pharmacology. 9, 482.
PNUD, Programa das Nações Unidas para o Desenvolvimento (2021). Ranking IDH Global 2014. www.br.undp.org/content/brazil/pt/home/idh0/rankings/idh-global.html.
Dias-Tosta, E., Rieder, C. R. M., Borges, V. & Neto, Y. C. (2010). Recomendações para o tratamento da doença de Parkinson. In: TOSTA, E. et al. Doença de Parkinson: recomendações. 1(2), 13-18.
Redone, Registros Brasileiros de Doenças Neurológicas (2021). Academia Brasileira de Neurologia: Registros Brasileiros de Doenças Neurológicas www.abneuro.org.br/redone.
Santos, V. L. (2015). Perfil epidemiológico da doença de Parkinson no Brasil. Centro Universitário de Brasília: Faculdade de Ciências da Educação E Saúde.
Silva, A. B. G. (2021). Doença de Parkinson: revisão de literatura. Revista Brazilian Journal of Development, 7(4).
Simon, D. K., Tanner, C. M. & Brundin, P.. (2019). Parkinson Disease Epidemiology, Pathology, Genetics, and Pathopshysiology. Clinics in geriatric medicine. 36(1), 1-12.
Souza, C. F. M., Almeida, H. C. P., Sousa, J. B., Costa, P. H., Silveira, Y. S. S. & Bezerra, J. C. L. (2011). A Doença de Parkinson e o Processo de Envelheci¬mento Motor: Uma Revisão de Literatura. Revista Neurociências, 14(4).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Giovanni Ferreira Santos; Guilherme de Queiroz Nunes e Silva; Douglas Ribeiro Moreira; Bruno Gontijo Vergutz; João Pedro de Miranda Carvalho; João Pedro Arruda Pessoa; Valter Paz do Nascimento Junior; Natalia Filardi Tafuri
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
